Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MVA-SIBP Vaccine for Mpox in DRC
NCT07253675Phase 2Not yet recruiting
- Sponsor
- Shanghai Institute of Biological Products
- Start
- Dec 2025
- Primary completion
- Feb 2027
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors, Oncolytic Viruses
01
Overview
A Phase 2 trial of MVA-SIBP in mpox, sponsored by Shanghai Institute of Biological Products. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
MVA-SIBP
03
Conditions
mpox
Beyond the preview
Go deeper on NCT07253675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07253675.